Related Experiment Video
Updated: Jun 23, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway
Kelly L Snider1, Michael L Maitland
1Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
Abstract:
Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing understanding of the mechanism of action of these drugs in the human cancer patient and the factors affecting the therapeutic index. In addition to reviewing current concepts for the cardiovascular toxicities of angiogenesis inhibitors, we discuss how better understanding the pharmacologic basis for these effects could optimize their use for individual patients.
Insights
Cardiovascular toxicities are a growing concern with angiogenesis inhibitors used in cancer treatment. Understanding their mechanisms can help optimize patient therapy and minimize side effects.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Angiogenesis inhibitors are increasingly used for cancer treatment.
- Cardiovascular toxicities are recognized side effects of these drugs.
- Understanding drug mechanisms is crucial for safe and effective use.
Purpose of the Study:
- To review current concepts of cardiovascular toxicities associated with angiogenesis inhibitors.
- To discuss the pharmacologic basis of these toxicities.
- To explore optimizing the use of these agents for individual cancer patients.
Main Methods:
- Literature review of angiogenesis inhibitors and their cardiovascular effects.
- Analysis of pharmacologic mechanisms underlying drug-induced cardiotoxicity.
- Discussion of therapeutic index factors and patient-specific optimization strategies.
Main Results:
- Cardiovascular toxicities are a class effect of angiogenesis inhibitors.
- Mechanisms of cardiotoxicity are being elucidated.
- Pharmacologic understanding can guide personalized treatment approaches.
Conclusions:
- Cardiovascular safety is a critical consideration in angiogenesis inhibitor therapy.
- Further research into drug mechanisms will improve patient outcomes.
- Optimizing treatment based on pharmacologic principles is essential for managing cancer patients.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Heart Failure Drugs: Inotropic Agents
Drug Toxicity: Risk factors
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Toxicity: Overview
